Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess

Clinical Drug Investigation

Volumn 28, Issue 2, 2008, Pages 71-79

  Rink, Andreas D ^a   Stass, Heino ^b   Delesen, Heinz ^b   Kubitza, Dagmar ^b   Vestweber, Karl Heinz ^a  

^a Leverkusen General Hospital   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

Abscess; Intra abdominal infections; Moxifloxacin, pharmacokinetics

Indexed keywords

MOXIFLOXACIN;

ABDOMINAL ABSCESS; ABSCESS DRAINAGE; ADULT; AEROBIC BACTERIUM; AGED; ANAEROBIC BACTERIUM; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PENETRATION; ECHOGRAPHY; FEMALE; HUMAN; LABORATORY TEST; MALE; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; OPEN STUDY; PERITONITIS; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; VITAL SIGN;

ABDOMINAL ABSCESS; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; BODY FLUIDS; BRADYCARDIA; DRAINAGE; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; KINETICS; MALE; MIDDLE AGED; QUINOLINES; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 38349164970     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828020-00001     Document Type: Article

References (28)

1. Goldstein EJC, Snydman DR. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004; 53 Suppl. S2: ii29-36
2. Nathans AB, Rotstein OD. Antimicrobial therapy for intraabdominal infection. Am J Surg 1996; 172 Suppl. 6A: 1S-6S
3. Solomkin JS, Mzauski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005
4. Falagas ME, Barefoot L, Griffith J, et al. Risk factors leading to clinical failure in the treatment of intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996; 15: 913-21
5. Mosdell DM, Morris DM, Voltura A, et al. Antibiotic treatment for surgical peritonitis. Ann Surg 1991; 214: 543-9
6. Hau T, Jacobs DE, Hawkins NL. Antibiotics fail to prevent abscess formation secondary to bacteria trapped in fibrin clots. Arch Surg 1986; 121: 163-8
7. Galandiuk S, Lamos J, Montgomery W, et al. Antibiotic penetration of experimental intra-abdominal abscesses. Am Surg 1995; 61: 521-5
8. Edmiston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48: 1012-6
9. Goldstein EJ, Citron DM, Merriam CV, et al. Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites. J Antimicrob Chemother 2002; 50: 411-20
10. Goldstein EJC, Citron DM, Warren YA, et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006; 50: 148-55
11. Cisneros RL, Onderdonk AB. Antimicrobial efficacy testing of moxifloxacin during the peritonitis and abscess formation stages of intra-abdominal sepsis: a controlled trial in the rat model. Curr Ther Res 2002; 63: 821-7
12. Cisneros RL, Onderdonk AB. Efficacy of moxifloxacin monotherapy versus gatifloxacin monotherapy, piperacillin-tazobactam combination therapy, and clindamycin plus gentamicin combination therapy: an experimental study in a rat model of intra-abdominal sepsis induced by fluoroquinolone-resistant Bacteroides fragilis. Curr Ther Res 2005; 66: 222-9
13. Eckhardt C, Fickweiler K, Schaumann R, et al. Therapeutic efficacy of moxifloxacin in a murine model of severe systemic mixed infection with Escherichia coli and Bacteroides fragilis. Anaerobe 2003; 9: 157-60
14. Schaumann R, Blatz R, Beer J, et al. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli. J Antimicrob Chemother 2004; 53: 318-24
15. Thadepalli H, Chuah SK, Gollapudi S. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice. Chemotherapy 2004; 50: 76-80
16. Wirtz M, Kleeff J, Swoboda S, et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004; 53: 875-7
17. Stass H, Dahloff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163-74
18. Wagner C, Sauermann R, Joukhadar C. Principles of antibiotic penetration into abscess fluid. Pharmacology 2006; 78: 1-10
19. Sauermann R, Karch R, Langenberger H, et al. Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother 2005; 49: 4448-54
20. Stearne LET, Gyssens IC, Goessens WHF, et al. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infections with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model. Antimicrob Agents Chemother 2001; 45: 1394-401
21. Barza M. Pharmacokinetics of antibiotics in shallow and deep compartments. J Antimicrob Chemother 1993; 31 Suppl. D: 17-27
22. Osenbach RK, Loftus CM. Diagnosis and management of brain abscess. Neurosurg Clin N Am 1992; 3: 403-20
23. Stass H, Rink AD, Delesen H, et al. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58: 693-6
24. Müller M, Stass H, Brunner M, et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345-9
25. Van Etta, LL, Peterson LR, et al. Effect of the ratio of surface area to volume on the penetration of antibiotics into extravascular spaces in an in vitro model. J Infect Dis 1982; 146: 423-8
26. Soussy CJ, Nguyen J, Goldstein F, et al. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study. Clin Microbiol Infect 2003; 9: 997-1005
27. Wenzler S, Schmidt-Eisenlohr E, Daschner F. Comparative in abvitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections. Chemotherapy 2004; 50: 40-2
28. Noel AR, Bowker KE, MacGowan AP. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2005; 49: 4234-9